Equity Profile

LIVN

LivaNova PLC

Health CareHealth Care Equipment$4.0B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

LivaNova PLC is a health care company that specializes in medical devices and therapies. With a market cap of $4 billion, it plays a crucial role in the health care equipment sector, focusing on innovative solutions for patients with cardiovascular and neurological conditions.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

Expected to be around $0.98.

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, crucial for long-term success.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

LIVN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+39.47%

Avg Stock Reaction

+2.92%

Last Quarter Recap

In Q1-2026, LivaNova reported an EPS of $0.98, significantly beating estimates by 36.11%. The stock reacted positively, increasing by 15.05% the next day.

Management Promises & Guidance

Continued focus on innovation in cardiovascular and neurological therapies.
Commitment to improving operational efficiency.
Plans to expand market reach in key therapeutic areas.

Expectations

Wall Street Expectations

Overall, expectations are high for LivaNova's upcoming earnings, especially given its strong track record of beating EPS estimates.

Bull Case

If LivaNova continues its trend of strong earnings surprises, it could see significant stock appreciation, especially if revenue growth is also strong.

Bear Case

Conversely, if the company fails to meet expectations or if there are signs of slowing growth, the stock could face downward pressure.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $0.98.

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

Revenue Growth

Not available.

Revenue growth reflects the company's ability to expand its market presence and sales, crucial for long-term success.

Market Reaction Post-Earnings

Historically, the stock has shown an average 1-day move of +10%.

Understanding how the stock typically reacts to earnings surprises can provide insights into investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given LivaNova's history of beating EPS estimates, this figure will be crucial in determining market reaction and investor confidence.

How is revenue growth tracking in key therapeutic areas?

Investors will closely monitor revenue growth to assess the company's market position and future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating LivaNova's potential for revenue growth in key therapeutic areas, especially given its recent innovations.

Supporting Evidence

LivaNova has consistently beaten EPS estimates, indicating stronger underlying performance than expected.

The options market is pricing in a larger move than historical averages suggest, indicating potential for a surprise.

Recent trends in the health care sector show increasing demand for innovative medical devices.

Key Risk

If revenue growth significantly outpaces expectations, it could lead to a reevaluation of the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating LivaNova's ability to sustain its strong performance amid competitive pressures and economic conditions.

Bull Confirmed If

An EPS of $1.05 or higher would confirm the bull case.

Bear Confirmed If

An EPS below $0.90 would raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±21.07%

Historical Avg

±10.0%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors anticipate volatility around the earnings report.

Options are pricing ±21.1% while LIVN has averaged ±10.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

55.5%

Calls (200)P/C Ratio: 0.67Puts (400)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If LivaNova beats expectations, history suggests the stock could rise by around +2.92%, confirming the company's strong growth narrative.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

A miss on EPS could lead to a decline of around -5.80%, reflecting concerns about the company's growth potential.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in cardiovascular therapies.
2Insights into market share changes in key segments.
3Management's outlook on regulatory challenges.
4Comments on operational efficiency improvements.
5Any guidance on future revenue growth expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

Expected to be around $0.98.

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, crucial for long-term success.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

LIVN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+39.47%

Avg Stock Reaction

+2.92%

Last Quarter Recap

In Q1-2026, LivaNova reported an EPS of $0.98, significantly beating estimates by 36.11%. The stock reacted positively, increasing by 15.05% the next day.

Management Promises & Guidance

Continued focus on innovation in cardiovascular and neurological therapies.
Commitment to improving operational efficiency.
Plans to expand market reach in key therapeutic areas.

Expectations

Wall Street Expectations

Overall, expectations are high for LivaNova's upcoming earnings, especially given its strong track record of beating EPS estimates.

Bull Case

If LivaNova continues its trend of strong earnings surprises, it could see significant stock appreciation, especially if revenue growth is also strong.

Bear Case

Conversely, if the company fails to meet expectations or if there are signs of slowing growth, the stock could face downward pressure.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $0.98.

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

Revenue Growth

Not available.

Revenue growth reflects the company's ability to expand its market presence and sales, crucial for long-term success.

Market Reaction Post-Earnings

Historically, the stock has shown an average 1-day move of +10%.

Understanding how the stock typically reacts to earnings surprises can provide insights into investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given LivaNova's history of beating EPS estimates, this figure will be crucial in determining market reaction and investor confidence.

How is revenue growth tracking in key therapeutic areas?

Investors will closely monitor revenue growth to assess the company's market position and future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating LivaNova's potential for revenue growth in key therapeutic areas, especially given its recent innovations.

Supporting Evidence

LivaNova has consistently beaten EPS estimates, indicating stronger underlying performance than expected.

The options market is pricing in a larger move than historical averages suggest, indicating potential for a surprise.

Recent trends in the health care sector show increasing demand for innovative medical devices.

Key Risk

If revenue growth significantly outpaces expectations, it could lead to a reevaluation of the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating LivaNova's ability to sustain its strong performance amid competitive pressures and economic conditions.

Bull Confirmed If

An EPS of $1.05 or higher would confirm the bull case.

Bear Confirmed If

An EPS below $0.90 would raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±21.07%

Historical Avg

±10.0%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors anticipate volatility around the earnings report.

Options are pricing ±21.1% while LIVN has averaged ±10.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

55.5%

Calls (200)P/C Ratio: 0.67Puts (400)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If LivaNova beats expectations, history suggests the stock could rise by around +2.92%, confirming the company's strong growth narrative.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

A miss on EPS could lead to a decline of around -5.80%, reflecting concerns about the company's growth potential.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in cardiovascular therapies.
2Insights into market share changes in key segments.
3Management's outlook on regulatory challenges.
4Comments on operational efficiency improvements.
5Any guidance on future revenue growth expectations.